Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY26 results · Jan–Mar 2026
Astec LifeSciences reported revenue from operations of ₹158.62 crore (up 32.7% from Q4 FY25) and net loss of ₹7.75 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 158.62 | 119.53 | +32.7% | 124.72 | +27.2% |
| Other income | 2.63 | 0.79 | +232.9% | 0.82 | +223.1% |
| Total income | 161.26 | 120.32 | +34.0% | 125.54 | +28.5% |
| Profit before tax | (7.90) | (15.66) | Loss narrowed | (15.68) | Loss narrowed |
| Net profit for the period | (7.75) | (16.08) | Loss narrowed | (15.69) | Loss narrowed |
| Attributable to shareholders of the company | (7.76) | (16.09) | Loss narrowed | (15.70) | Loss narrowed |
| EPS, basic (₹) | (3.48) | (8.20) | Loss narrowed | (7.04) | Loss narrowed |
| Net margin (%) | -4.9 | -13.5 | -12.6 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 158.62 | 119.53 | +32.7% | 124.72 | +27.2% |
| Other income | 2.61 | 0.78 | +236.3% | 0.79 | +229.4% |
| Total income | 161.24 | 120.30 | +34.0% | 125.51 | +28.5% |
| Profit before tax | (7.94) | (15.69) | Loss narrowed | (15.72) | Loss narrowed |
| Net profit for the period | (7.78) | (16.10) | Loss narrowed | (15.72) | Loss narrowed |
| EPS, basic (₹) | (3.49) | (8.21) | Loss narrowed | 7.06 | Turned loss |
| Net margin (%) | -4.9 | -13.5 | -12.6 |
Consolidated
- Filed with BSE
- 27 Apr 2026, 22:07 IST
- Board meeting
- 27 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Apr 2026, 22:07 IST
- Board meeting
- 27 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE